Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone (BMT CTN 1705)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04167514|
Recruitment Status : Recruiting
First Posted : November 19, 2019
Last Update Posted : December 20, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Graft Versus Host Disease (GVHD)||Biological: Alpha-1 antitrypsin (AAT) Drug: Placebo||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||136 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Trial of Alpha 1 - Antitrypsin (AAT) Combined With Corticosteroids vs Corticosteroids Alone for the Treatment of High Risk Acute Graft-versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplant (BMT CTN 1705)|
|Actual Study Start Date :||January 9, 2020|
|Estimated Primary Completion Date :||May 2024|
|Estimated Study Completion Date :||May 2024|
Alpha-1 antitrypsin (AAT) is a lyophilized powder for intravenous administration
Biological: Alpha-1 antitrypsin (AAT)
AAT is a lyophilized product for intravenous administration
Other Name: Alpha-1 proteinase inhibitor (A1-P1)
Placebo Comparator: Placebo
Albumin solution administered intravenously
Albumin solution administered intravenously
- Percent of participants with complete or partial response to acute Graft-versus-Host Disease (GVHD) treatment [ Time Frame: 28 days post-randomization ]
Acute GVHD will be graded and assessed for response based on Harris criteria (stage 0, 1, 2, 3, 4) for skin, liver, upper gastrointestinal (GI) tract, and lower GI tract. Complete response (CR) is defined as a score of 0 for the GVHD staging in all evaluable organs.
Partial response (PR) is defined as improvement in one or more organs involved with GVHD symptoms without progression in others.
- Duration of response (DOR) [ Time Frame: up to 12 months post-randomization ]DOR is defined as time from the Day 28 response (CR or PR) to any of the following events: relapse/progression of acute GVHD, new systemic salvage therapy for acute GVHD, re-escalation of steroids to greater or equal to 2.5 mg/kg prednisone or equivalent, or death from any cause.
- Percent of participants with non-relapse mortality (NRM) [ Time Frame: up to 12 months post-randomization ]An event of NRM is death without prior evidence of relapse/progression of the primary disease, where relapse/progression is treated as a competing risk.
- Percent of participants with overall survival and progression-free survival [ Time Frame: up to 12 months post-randomization ]An event for overall survival is death from any cause, while an event for progression-free survival is death from any cause or relapse/progression of the primary disease.
- Percent of participants with GVHD-free survival [ Time Frame: Day 56 post-randomization ]Patients alive, free of active acute or chronic GVHD, and without other systemic agents or escalation of steroids added for treatment of GVHD will be considered successes for this endpoint.
- Percent of participants with response [ Time Frame: At Day 7, 14, 21, 28, 56, and 86 post-randomization ]The proportion of patients with CR, PR (including subset with VGPR), and treatment failure (TF). The designation of TF will consist of patients with no response (NR), mixed response (MR), progression or initiation of additional systemic (second-line) GVHD therapies or escalation of steroids. Death from any cause will also be considered a TF.
- Percent of participants with Grade 2 to 3 systemic infections [ Time Frame: up to 30 days after the last dose of study drug ]The incidence of Grade 2 to 3 systemic infections. Grade 2 to 3 systemic infections will be defined according to BMT CTN Manual of Procedures.
- Percent of participants with Grade 3 to 5 treatment-emergent adverse events (TEAEs) [ Time Frame: up to 30 days after the last dose of study drug ]The incidence of Grade 3 to 5 TEAEs (per Common Terminology Criteria for Adverse Events [CTCAE] Version 5.0)
- Percent of participants with chronic GVHD [ Time Frame: up to 12 months post-randomization ]Chronic GVHD is defined per National Institutes of Health (NIH) Consensus Criteria. Diagnosis of chronic GVHD of any severity (mild, moderate, or severe) is considered an event for this endpoint.
- Percent of participants with disease relapse [ Time Frame: up to 12 months post-randomization ]The cumulative incidence of relapse/progression of the primary disease, with death prior to relapse/progression treated as a competing risk.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||12 Years and older (Child, Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Patients 12 years of age or older
- Initial presentation of acute GVHD after allogeneic hematopoietic cell transplantation for any indication
- Any graft or donor source or conditioning intensity
- Clinical diagnosis of acute GVHD requiring systemic therapy with corticosteroids
- Prior exogenous AAT exposure for GVHD prophylaxis
- Relapsed, progressing, or persistent malignancy
- de novo chronic GVHD or overlap syndrome developing before or present at the time of enrollment
- Receiving other drugs for the treatment of GVHD
- Receiving systemic CS for any indication within 7 days before the onset of acute GVHD
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04167514
|Contact: Trial Registration Coordinatoremail@example.com|
|Study Director:||Study Director||CSL Behring|
|Responsible Party:||CSL Behring|
|Other Study ID Numbers:||
CSL964_5001 / BMT CTN 1705
BMT CTN Protocol 1705 ( Other Identifier: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) )
|First Posted:||November 19, 2019 Key Record Dates|
|Last Update Posted:||December 20, 2022|
|Last Verified:||December 2022|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||Yes|
CSL will consider requests to share Individual Patient Data (IPD) from systematic review groups or bona-fide researchers. For information on the process and requirements for submitting a voluntary data sharing request for IPD, please contact CSL at firstname.lastname@example.org.
Applicable country specific privacy and other laws and regulations will be considered and may prevent sharing of IPD.
If the request is approved and the researcher has executed an appropriate data sharing agreement, IPD that has been appropriately anonymized will be available.
Statistical Analysis Plan (SAP)
|Time Frame:||IPD requests may be submitted to CSL no earlier than 12 months after publication of the results of this study via an article made available on a public website.|
Requests may only be made by systematic review groups or bona-fide researchers whose proposed use of the IPD is non-commercial in nature and has been approved by an internal review committee.
An IPD request will not be considered by CSL unless the proposed research question seeks to answer a significant and unknown medical science or patient care question as determined by CSL's internal review committee.
The requesting party must execute an appropriate data sharing agreement before IPD will be made available.
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
Graft vs Host Disease
Immune System Diseases
Protein C Inhibitor
Molecular Mechanisms of Pharmacological Action
Serine Proteinase Inhibitors